SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...

Edwards Lifesciences (NYSE:EW) today unveiled its “Stay in the Race” initiative to support heart valve health.

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration recently cleared the line of catheter-based heart valves, which includes Sapien ...

Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...